Skystar Bio-pharmaceutical Co. (fka SKBI)

[236T568]

So tell us again how a corporate governance issue results in all the cash, $16 million worth, being missing from the SKBI bank accounts and the failure to collect 2 months worth of revenues, $24 million, when previous financials showed that the $24 million was collected.

In addition to the fraudulent bank statements provided by the company to the auditors, you have one big scam company here!

Look, Nasdaq are as clueless as they come. Obviously the company investigated the matter, how else could they fire the employee?
What this is, or could be, is a corporate governance issue. At an earlier stage.